Unbiased screening of protein and/or peptide levels in CSF, in relation to changes of the traditional Ab and tau biomarkers in a clinically diverse cohort, could help identify distinct markers related to glucose metabolism that are altered in AD as opposed to other neurological processes. This evidence concerns the gene MAPT and Alzheimer disease.